Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Provided By GlobeNewswire
Last update: Dec 11, 2024
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D
Read more at globenewswire.com
